Increase of ciprofloxacin resistance in Campylobacter species in Styria, Austria

Antibiotic Resistance Among Campylobacter jejuni/coli Strains Acquired in Sweden and Abroad: A Longitudinal Study

Antibiotic resistance was compared in 844 Campylobacter jejuni/coli strains acquired outside Sweden and 575 acquired in Sweden during 1990-2002. There was a clear gradual increase in ciprofloxacin and tetracycline resistance among C. jejuni/coli strains acquired outside Sweden during the 13 y period. This trend was not seen for erythromycin or in domestically acquired strains for any of the 3 antibiotics tested.

Campylobacteriosis in Austria: situation and trends

Campylobacter species are among the most commonly identified causative agents of acute bacterial gastroenteritis in humans worldwide. In Austria, campylobacteriosis has been a notifiable disease since 1996 and its incidence has increased continuously over the past years. Improvement of notification has led to an important increase in knowledge of the epidemiology of this disease in Austria. In addition to existing programs monitoring food safety, implementation of a national surveillance program to monitor antimicrobial resistance and the prevalence of campylobacter in food animals allows continuous surveillance of trends in antimicrobial susceptibility patterns in humans, animals and food, as well as a more comprehensive evaluation of the occurrence of campylobacter in the relevant reservoirs of human infection. Such data make it possible to identify the most important areas for intervention and launch of control strategies. As in other countries around the world, antimicrobial resistance of campylobacter from human, animal and food origin, particularly resistance to fluoroquinolones, is of public health concern in Austria. The magnitude of global trade and foreign travel requires EU-wide and worldwide implementation of control strategies to fight campylobacteriosis.

Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates

The incidence of human Campylobacter jejuni and C. coli infections has increased markedly in many parts of the world in the last decade as has the number of quinolone-resistant and, to a lesser extent, macrolide-resistant Campylobacter strains causing infections. We review macrolide and quinolone resistance in Campylobacter and track resistance trends in human clinical isolates in relation to use of these agents in food animals. Susceptibility data suggest that erythromycin and other macrolides should remain the drugs of choice in most regions, with systematic surveillance and control measures maintained, but fluoroquinolones may now be of limited use in the empiric treatment of Campylobacter infections in many regions.